Clinical Trials Logo

Recurrent Squamous Cell Lung Carcinoma clinical trials

View clinical trials related to Recurrent Squamous Cell Lung Carcinoma.

Filter by:

NCT ID: NCT03373760 Recruiting - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Start date: October 2, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well durvalumab and tremelimumab works in treating patients with stage IV lung cancer that has come back after previous treatment. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02965378 Active, not recruiting - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Start date: June 16, 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II/III trial studies how well FGFR inhibitor AZD4547 (AZD4547) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the fibroblast growth factor receptor (FGFR) biomarker. FGFR can cause tumor cells to grow more quickly. AZD4547 may decrease the activity of FGFR and may be able to shrink tumors.

NCT ID: NCT02926638 Active, not recruiting - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Start date: June 16, 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This randomized phase II/III compares rilotumumab when given together with erlotinib hydrochloride against erlotinib hydrochloride alone in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the met proto-oncogene (MET)/hepatocyte growth factor (HGF) biomarker. HGF can interact with MET and can cause tumor cells to grow more quickly. Rilotumumab may decrease the activity of HGF and may be able to shrink tumors. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving rilotumumab with erlotinib hydrochloride works better than erlotinib hydrochloride alone (standard treatment) in treating squamous cell lung cancer.

NCT ID: NCT02785952 Recruiting - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Start date: December 18, 2015
Phase: Phase 3
Study type: Interventional

This randomized phase III trial compares nivolumab with ipilimumab and nivolumab alone in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a "non-match" sub-study that includes all screened patients not eligible for a biomarker-driven sub-study. Monoclonal antibodies, such as nivolumab and ipilimumab, may be able to shrink tumors. It is not yet known whether nivolumab works better with or without ipilimumab in treating patients with squamous cell lung cancer.

NCT ID: NCT02785939 Active, not recruiting - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Start date: June 16, 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II/III trial studies how well palbociclib works in treating cell cycle gene alteration positive patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for cell cycle gene alterations which can cause tumor cells to grow more quickly. Palbociclib may slow cell cycle progression and may be able to shrink tumors.

NCT ID: NCT02785913 Active, not recruiting - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

S1400B Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Start date: June 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well taselisib (GDC-0032) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the phosphoinositide 3-kinase (PI3K) biomarker. PI3K can cause tumor cells to grow more quickly. Taselisib may decrease the activity of PI3K and may be able to shrink tumors.

NCT ID: NCT02766335 Active, not recruiting - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Start date: June 16, 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II trial studies how well durvalumab works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a "non-match" sub-study that includes all screened patients not eligible for a biomarker-driven sub-study. Monoclonal antibodies, such as durvalumab, may be able to shrink tumors. Durvalumab may be effective in treating patients with squamous cell lung cancer.

NCT ID: NCT02536495 Withdrawn - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

Start date: September 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of selinexor and docetaxel and to see how well they work when given together in treating patients with squamous cell lung cancer that has come back or spread to other places in the body. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving selinexor together with docetaxel may work better in treating squamous cell lung cancer.

NCT ID: NCT02417701 Recruiting - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

TORC1/2 Inhibitor MLN0128 in Treating Patients With Stage IV or Recurrent Lung Cancer

Start date: October 6, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well target of rapamycin complex 1/2 (TORC1/2) inhibitor MLN0128 works in treating patients with lung cancer that is stage IV or has come back (recurrent) and has a mutation in the nuclear factor, erythroid 2-like 2 (NFE2L2) or kelch-like ECH-associated protein 1 (KEAP1) gene. Damage to these genes may cause the cancer to grow. TORC1/2 inhibitor MLN0128 may stop this from happening by blocking enzymes.

NCT ID: NCT02154490 Recruiting - Clinical trials for Recurrent Squamous Cell Lung Carcinoma

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Start date: June 16, 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a ?non-match? sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.